These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33404120)

  • 1. Scandalous decisions: explaining shifts in UK medicinal cannabis policy.
    Monaghan M; Wincup E; Hamilton I
    Addiction; 2021 Jul; 116(7):1925-1933. PubMed ID: 33404120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Children as voices and images for medicinal cannabis law reform.
    Freckelton Ao Qc I
    Monash Bioeth Rev; 2021 Dec; 39(Suppl 1):4-25. PubMed ID: 34719005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observations of the role of science in the United States medical cannabis state policies: Lessons learnt.
    Grbic J; Goddard P; Ryder D
    Int J Drug Policy; 2017 Apr; 42():109-114. PubMed ID: 28190671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "It's a big added stress on top of being so ill": The challenges facing people prescribed cannabis in the UK.
    Beckett Wilson H; Metcalf McGrath L
    Int J Drug Policy; 2023 Dec; 122():104220. PubMed ID: 37806073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEDICINAL CANNABIS LAW REFORM IN AUSTRALIA.
    Freckelton I
    J Law Med; 2016 Mar; 23(3):497-515. PubMed ID: 27323630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Making medicine; producing pleasure: A critical examination of medicinal cannabis policy and law in Victoria, Australia.
    Lancaster K; Seear K; Ritter A
    Int J Drug Policy; 2017 Nov; 49():117-125. PubMed ID: 28886887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The three betrayals of the medical cannabis growing activist: From multiple victimhood to reconstruction, redemption and activism.
    Klein A; Potter GR
    Int J Drug Policy; 2018 Mar; 53():65-72. PubMed ID: 29287224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is cannabis an illicit drug or a medicine? A quantitative framing analysis of Israeli newspaper coverage.
    Sznitman SR; Lewis N
    Int J Drug Policy; 2015 May; 26(5):446-52. PubMed ID: 25661483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NICE Guideline On Medicinal Cannabis: Keeping Pandora's Box Shut Tight?
    Case P
    Med Law Rev; 2020 May; 28(2):401-411. PubMed ID: 32016366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scandals in health-care: their impact on health policy and nursing.
    Hutchison JS
    Nurs Inq; 2016 Mar; 23(1):32-41. PubMed ID: 26189555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Policy Governance in the UK: lessons from changes to and debates concerning the classification of cannabis under the 1971 Misuse of Drugs Act.
    Monaghan M
    Int J Drug Policy; 2014 Sep; 25(5):1025-30. PubMed ID: 24635973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based policy? The re-medicalization of cannabis and the role of expert committees in the UK, 1972-1982.
    Taylor SL
    Int J Drug Policy; 2016 Nov; 37():129-135. PubMed ID: 27477790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epilepsy and cannabis: so near, yet so far.
    Kirkpatrick M; O'callaghan F
    Dev Med Child Neurol; 2022 Feb; 64(2):162-167. PubMed ID: 34498262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six policy lessons relevant to cannabis legalization.
    Shover CL; Humphreys K
    Am J Drug Alcohol Abuse; 2019; 45(6):698-706. PubMed ID: 30870053
    [No Abstract]   [Full Text] [Related]  

  • 15. So near yet so far: why won't the UK prescribe medical cannabis?
    Nutt D; Bazire S; Phillips LD; Schlag AK
    BMJ Open; 2020 Sep; 10(9):e038687. PubMed ID: 32958492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using Therapeutic Drug Monitoring and Pharmacovigilance to Overcome Some of the Challenges of Developing Medicinal Cannabis from Botanical Origins.
    Dryburgh LM; Martin JH
    Ther Drug Monit; 2020 Feb; 42(1):98-101. PubMed ID: 31479044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….
    Baron EP
    Headache; 2015 Jun; 55(6):885-916. PubMed ID: 26015168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
    Rychert M; Wilkins C
    Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Media Framing of Causes, Risks, and Policy Solutions for Cannabis-Impaired Driving: Does Medical vs. Non-Medical Cannabis Context Matter?
    Lewis N; Eliash-Fizik H; Har-Even A; Sznitman SR
    Health Commun; 2024 Apr; 39(4):828-837. PubMed ID: 36914573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marijuana in the Workplace: Guidance for Occupational Health Professionals and Employers: Joint Guidance Statement of the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine.
    Phillips JA; Holland MG; Baldwin DD; Gifford-Meuleveld L; Mueller KL; Perkison B; Upfal M; Dreger M
    Workplace Health Saf; 2015 Apr; 63(4):139-64. PubMed ID: 25862727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.